Vascular, cardiac & structural
One of 5 mechanistic pathways to 🧬 Organ-specific bioregulation · 7 options
The tissues where age-related decline is most measurable — and where, if a tissue-specific signal did what the theory claims, you would expect to be able to detect it.
Vascular and cardiac endpoints are measurable, which makes this the easiest place to hold the bioregulator claims to account. Baseline first.
ApoB (Apolipoprotein B)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)hs-CRP (High-Sensitivity C-Reactive Protein)High-Sensitivity Troponin TVitamin D (25-Hydroxy)🫀 Real Cardiovascular Risk covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Cardiogen
Cardiac muscle bioregulator, proposed to restore age-declined gene expression in cardiomyocytes. Mechanistically the most metabolically demanding tissue to target, and untested outside the programme.
💉 Chelohart
Oral cardiac peptide from the same series.
💉 Ventfort
Vascular wall bioregulator, proposed to support endothelial function.
💉 Vesugen
The synthetic vascular tripeptide (Lys-Glu-Asp).
💉 Cartalax
Cartilage bioregulator — the tissue with the least regenerative capacity, which makes it both the most interesting target and the hardest claim.
💉 Sigumir
Cartilage and bone bioregulator. If the tissue-specific theory holds anywhere it would matter most here, since cartilage has almost no regenerative capacity of its own.
💉 Bolamin
Connective tissue and bone bioregulator.
The other 4 routes to organ-specific bioregulation
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
Want the protocols behind these?
Dosing schedules, stacking, cycle timing and Coach Cam's notes live inside the Academy — plus the full interactive Vault.
Join the Academy — $10/mo →← Open this pathway in the interactive Vault
Frequently asked questions
The tissues where age-related decline is most measurable — and where, if a tissue-specific signal did what the theory claims, you would expect to be able to detect it.
7 options are mapped to this pathway in the Vault, including Cardiogen, Chelohart, Ventfort, Vesugen. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 0 carry clinical validation and 7 are mechanistic predictions.
Vascular and cardiac endpoints are measurable, which makes this the easiest place to hold the bioregulator claims to account. Baseline first. The markers worth checking are ApoB (Apolipoprotein B), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein), High-Sensitivity Troponin T.
Unproven is not the same as ineffective. Of the 7 options on this pathway, 0 have clinical validation and 7 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.